Improved Innate Immune Function in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Therapy in Clinical Trials

CONCLUSIONS: Innate immune impairment and infection susceptibility in CLL patients were restored in parallel during targeted therapy. Thus, targeted treatment may reduce the risk of infections in CLL, as currently under investigation in the PreVent-ACaLL phase 2 trial of acalabrutinib+venetoclax for high risk CLL (NCT03868722).PMID:38393694 | DOI:10.1158/1078-0432.CCR-23-2522

Source: Clinical Cancer Research - February 23, 2024 Category: Cancer & Oncology Authors: Rebecca Svanberg Teglgaard Hanne Vibeke Marquart Hans Jakob Hartling Jakob Thaning Bay Caspar da Cunha-Bang Christian Brieghel Tereza Faitov á Lisbeth Enggaard Arnon P Kater Mark-David Levin Sabina Kersting Sisse Rye Ostrowski Carsten U Niemann Source Type: research